We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Growing European Market for Nucleic Acid Isolation

By Biotechdaily staff writers
Posted on 25 Jul 2006
The significance of nucleic acid and its many applications in a large number of research fields has increased the demand for pure isolations in Europe. More...
Because nucleic acid is the fundamental substance preceding all other procedures in drug research, its integrity can enhance or damage research quality.

Frost & Sullivan (Palo Alto, CA, USA), an international growth consultancy company, finds that genomics markets/nucleic acid isolation markets in Europe earned revenues of U.S.$670.0 million in 2005 and estimates this will reach $1,490.2 million in 2012.

Incorporation of automation and robotics in the isolation of nucleic acid also plays a crucial role in meeting demand for purity. Further technologic value addition will only spur the instrumentation revenues in the market.

In this environment, automation has become instrumental in optimizing sample preparation stages--particularly for low- and medium-throughput operations. Suppliers of automation equipment to research institutions and pharmaceutical companies continually try to meet customers' demand for an open platform technology base with reagents and consumables.

"Automation vendors are working toward knowing their customers' needs, and customizing their solutions to ensure maximum satisfaction,” remarked Frost & Sullivan research analyst Charanya Ramachandran.

The market is very dynamic as brand restrictions and customer loyalty present problems for new participants. There is tremendous competition within the DNA as well as the RNA segments, which challenges an entrant to the market. Most end-users in this market give importance to reliability in their instrumentation suppliers, and therefore, brand loyalty is very high. Vendors with enough visibility and a proven market record, particularly in the case of reagents and purification kits that produce nucleic acid molecules with maximum purity, are able to make profits.

The best strategy for a niche participant would be to form a strategic alliance with a larger brand to gain better visibility. Furthermore, suppliers could offer a complete optimal cost solutions base using innovative technology, since the demand for stand-alone purification instrumentation is not very high.

"Some factors which can enhance a company's position within the market include forming strategic alliances or exclusive licensing agreements with a major innovative technology vendor,” noted Ms. Ramachandran.

Reliable service, accuracy, and quality, as well as attractive customer schemes could gain customer loyalty over time. Established suppliers could maintain and increase their base by building on customer loyalties through loyalty programs and a combination of selling and pricing strategies.



Related Links:
Frost & Sullivan

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Immunoassay Analyzer
Procise DX
Automatic CLIA Analyzer
Shine i6000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: iStock

Blood Test Measuring Tumor Proliferation May Guide Treatment Sequencing in Metastatic Melanoma

Metastatic melanoma remains difficult to manage because outcomes vary widely and early prognostic markers are limited. About half of patients carry a BRAF gene mutation, giving clinicians several first-line... Read more

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

Comprehensive Genomic Testing Expands Treatment Options for Advanced Cancers

Selecting effective therapies for advanced cancers remains difficult because standard tumor testing often targets only a limited set of genes. As options dwindle, many patients face decisions without strong... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.